AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27830924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha Yoga (HY)
Number of subjects: 36
Study 27830924 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training Program (CTP)
Number of subjects: 36
Study 25557731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% fractional inspired O2)
Number of subjects: 15
Study 25557731 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia (21% fractional inspired O2)
Number of subjects: 15
Study 25557731 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy adults)
Number of subjects: 15
Study 24290977 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-access carpal tunnel release (MACTR)
Number of subjects: 120
Study 24290977 — intervention group
Group type: COMPARATOR
Intervention: Traditional open carpal tunnel release (TOCTR)
Number of subjects: 120
Study 21114791 — intervention group
Group type: EXPERIMENTAL
Intervention: HMPL-004 1200 mg/day
Number of subjects: 120
Study 21114791 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine 4500 mg/day
Number of subjects: 120
Study 19526394 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion
Number of subjects: 30
Study 19526394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18049171 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2.87±0.67 mg)
Number of subjects: 48
Study 18049171 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (1.82±0.71 mg) with Meperidine (42.81±14.61 mg)
Number of subjects: 48
Study 15453924 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan 0.4 mCi/kg (n = 73)
Number of subjects: 143
Study 15453924 — intervention group
Group type: COMPARATOR
Intervention: Rituximab 375 mg/m2 I.V. weekly for 4 doses (n = 70)
Number of subjects: 143
Study 15453924 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan
Number of subjects: 143
Study 15453924 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 143
Study 15453924 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan (in patients achieving CR/CRu)
Number of subjects: 143
Study 15453924 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (in patients achieving CR/CRu)
Number of subjects: 143
Study 11438320 — intervention group
Group type: EXPERIMENTAL
Intervention: Repronex SC
Number of subjects: 115
Study 11438320 — intervention group
Group type: COMPARATOR
Intervention: Repronex IM
Number of subjects: 115
Study 11438320 — intervention group
Group type: COMPARATOR
Intervention: Pergonal IM
Number of subjects: 115
Study 9539992 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 27
Study 9539992 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 7527170 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative oral dose of 400 mg lomefloxacin
Number of subjects: 60
Study 7527170 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative oral dose of 400 mg lomefloxacin followed by 400 mg daily for 3 days
Number of subjects: 60
Study 7527170 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial prophylaxis
Number of subjects: 60
Study 30139908 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 0
Study 30139908 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 0
Study 27668698 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg propiverine hydrochloride (P4) t.i.d. from day 1 to day 7
Number of subjects: 48
Study 27668698 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (PL)
Number of subjects: 48
Study 27668698 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg propiverine hydrochloride (P4)
Number of subjects: 48
Study 25556817 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-fructose (GF)
Number of subjects: 20
Study 25556817 — intervention group
Group type: COMPARATOR
Intervention: Glucose-only (G)
Number of subjects: 20
Study 23743458 — intervention group
Group type: EXPERIMENTAL
Intervention: Three video teaching sessions with University of California, San Francisco faculty
Number of subjects: 18
Study 23743458 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 18
Study 21967940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated paste (Dentsply, York, Pa)
Number of subjects: 34
Study 21967940 — intervention group
Group type: COMPARATOR
Intervention: Plain pumice (Ortho Technology, Tampa, Fla)
Number of subjects: 34
Study 18155504 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave obturation with ProFile 29 Series rotary system
Number of subjects: 36
Study 18155504 — intervention group
Group type: COMPARATOR
Intervention: Endo‐Eze system
Number of subjects: 36
Study 16938024 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory linguistic cues
Number of subjects: 91
Study 16938024 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual linguistic cues
Number of subjects: 91
Study 16938024 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory and visual linguistic cues with distractors
Number of subjects: 91
Study 14512131 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath holding for 0 seconds
Number of subjects: 21
Study 14512131 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath holding for 3 seconds
Number of subjects: 21
Study 14512131 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath holding for 10 seconds
Number of subjects: 21
Study 10829313 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy combined with surgery
Number of subjects: 0
Study 10829313 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 9352870 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (IFN‐alpha) therapy
Number of subjects: 103
Study 8408979 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning light treatment (ML)
Number of subjects: 27
Study 8408979 — intervention group
Group type: COMPARATOR
Intervention: Evening light treatment (EL)
Number of subjects: 27
Study 8408979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ML and EL
Number of subjects: 27
Study 3955198 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg regular megestrol acetate tablet
Number of subjects: 24
Study 3955198 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg micronized megestrol acetate tablet
Number of subjects: 24
Study 3955198 — intervention group
Group type: COMPARATOR
Intervention: 40 mg megestrol acetate tablet (Megace)
Number of subjects: 24
Study 30161213 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-Based Goals and Incentives
Number of subjects: 983
Study 27405322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 27405322 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 0
Study 25202173 — intervention group
Group type: EXPERIMENTAL
Intervention: TA and PFM co-contraction exercise group (n=9)
Number of subjects: 15
Study 25202173 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=6)
Number of subjects: 15
Study 23018469 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg every 12 hours in obese pregnant women with T2DM
Number of subjects: 17
Study 23018469 — intervention group
Group type: COMPARATOR
Intervention: Metformin 850 mg every 12 hours in non-diabetic obese pregnant women with PCOS
Number of subjects: 17
Study 19910173 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechin (500 microg) with antitubercular treatment (ATT)
Number of subjects: 200
Study 19910173 — intervention group
Group type: COMPARATOR
Intervention: Starch (500 microg) with ATT (Control)
Number of subjects: 200
Study 18626312 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-275 3 mg biweekly (days 1+15, arm A)
Number of subjects: 28
Study 18626312 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-275 7 mg weekly (days 1+8+15, arm B)
Number of subjects: 28
Study 18626312 — intervention group
Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 28
Study 18626312 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-275
Number of subjects: 28
Study 16043728 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention in intervention clinics, involving training in a seven-step QI change process over an 18-month period.
Number of subjects: 754
Study 16043728 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (no QI intervention).
Number of subjects: 754
Study 12394910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spine radiography
Number of subjects: 421
Study 12394910 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 421
Study 10422533 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster paced trials
Number of subjects: 0
Study 10422533 — intervention group
Group type: COMPARATOR
Intervention: Self-paced trials
Number of subjects: 0
Study 7751822 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin (40 mg b.i.d.) + low cholesterol diet (mean 246 mg/day)
Number of subjects: 12
Study 7751822 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin + high cholesterol diet (mean 1071 mg/day)
Number of subjects: 12
Study 7751822 — intervention group
Group type: COMPARATOR
Intervention: low cholesterol diet alone
Number of subjects: 12
Study 7751822 — intervention group
Group type: COMPARATOR
Intervention: high cholesterol diet alone
Number of subjects: 12
Study 2255263 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestriol (3 mg/day for 4 weeks followed by 2 mg/day for a further 6 weeks)
Number of subjects: 35
Study 2255263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6164789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 43
Study 6164789 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 43
Study 30786997 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction at 41 weeks
Number of subjects: 1801
Study 30786997 — intervention group
Group type: COMPARATOR
Intervention: Expectant management until 42 weeks
Number of subjects: 1801
Study 28291046 — intervention group
Group type: COMPARATOR
Intervention: Deep dry needling (DDN) with no local twitch responses (LTRs) elicited
Number of subjects: 84
Study 28291046 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) with four LTRs elicited
Number of subjects: 84
Study 28291046 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) with six LTRs elicited
Number of subjects: 84
Study 28291046 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) until no more LTRs were elicited
Number of subjects: 84
Study 27025903 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 therapy
Number of subjects: 350
Study 27025903 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin therapy
Number of subjects: 350
Study 24148703 — intervention group
Group type: EXPERIMENTAL
Intervention: Netmums Helping With Depression (NetmumsHWD)
Number of subjects: 83
Study 24148703 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 83
Study 22397624 — intervention group
Group type: EXPERIMENTAL
Intervention: Offer for a free on-line CME activity
Number of subjects: 8477
Study 22397624 — intervention group
Group type: COMPARATOR
Intervention: No offer of CME credit (Control)
Number of subjects: 8477
Study 18930988 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with methotrexate (MTX) plus infliximab (IFX)
Number of subjects: 184
Study 18930988 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment with methotrexate (MTX) plus infliximab (IFX)
Number of subjects: 184
Study 17444858 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol 900 IU/day
Number of subjects: 50
Study 17444858 — intervention group
Group type: EXPERIMENTAL
Intervention: fermented papaya preparation (FPP) 9 g/day
Number of subjects: 50
Study 17444858 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 healthy subjects)
Number of subjects: 50
Study 16237479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoid therapy
Number of subjects: 0
Study 11866174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsuicidal self-injury
Number of subjects: 75
Study 11866174 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide attempts
Number of subjects: 75
Study 11866174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of parasuicide
Number of subjects: 75
Study 10221185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 1% instilled at 30 minute intervals for 24 hours
Number of subjects: 74
Study 10221185 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 0.1% instilled four times a day for 3 days
Number of subjects: 74
Study 10221185 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Diantalvic (paracetamol-noramidopyrine) as rescue analgesic
Number of subjects: 74
Study 10221185 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog pain charts
Number of subjects: 74
Study 10221185 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective questionnaire
Number of subjects: 74
Study 10221185 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer analysis of photography
Number of subjects: 74
Study 7879762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing elastomers
Number of subjects: 24
Study 7879762 — intervention group
Group type: COMPARATOR
Intervention: Conventional elastomers
Number of subjects: 24
Study 2193475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 10 mg intravenously
Number of subjects: 25
Study 2193475 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 25
Study 6998868 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 59
Study 31747465 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg kg‐1)
Number of subjects: 13
Study 31747465 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 13
Study 30348514 — intervention group
Group type: EXPERIMENTAL
Intervention: ALKS 3831 10/10 (10‐mg olanzapine/10‐mg samidorphan)
Number of subjects: 42
Study 30348514 — intervention group
Group type: EXPERIMENTAL
Intervention: ALKS 3831 20/10 (20‐mg olanzapine/10‐mg samidorphan)
Number of subjects: 42
Study 30348514 — intervention group
Group type: COMPARATOR
Intervention: ALKS 3831 (both doses)
Number of subjects: 42
Study 30348514 — intervention group
Group type: COMPARATOR
Intervention: ALKS 3831
Number of subjects: 42
Study 26808827 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 150
Study 26808827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 24774670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum CECT 7347 (10⁹ colony-forming units)
Number of subjects: 33
Study 24774670 — intervention group
Group type: COMPARATOR
Intervention: Placebo (excipients)
Number of subjects: 33
Study 22809026 — intervention group
Group type: EXPERIMENTAL
Intervention: Semen Vaccariae
Number of subjects: 56
Study 22809026 — intervention group
Group type: COMPARATOR
Intervention: Japanese Magnetic Pearl
Number of subjects: 56
Study 20424282 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy; specific dosage and duration not mentioned.
Number of subjects: 0
Study 20424282 — intervention group
Group type: COMPARATOR
Intervention: No treatment; control group not explicitly mentioned.
Number of subjects: 0
Study 18791892 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional weekly sessions (TWS)
Number of subjects: 86
Study 18791892 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal therapist contact (MTC)
Number of subjects: 86
Study 15998750 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for fibromyalgia
Number of subjects: 100
Study 15998750 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (pooled from 3 types)
Number of subjects: 100
Study 12571527 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 474
Study 12571527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study 11044144 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard and telephone call reminders (n = 306)
Number of subjects: 1273
Study 11044144 — intervention group
Group type: EXPERIMENTAL
Intervention: Kept appointments
Number of subjects: 1273
Study 11044144 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminders
Number of subjects: 1273
Study 11044144 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard and telephone reminders
Number of subjects: 1273
Study 8807168 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (RivP 18, 15, 12, 9 and 0 mg.kg‐1.hr‐1)
Number of subjects: 20
Study 8807168 — intervention group
Group type: COMPARATOR
Intervention: Halothane (F1H 2%, 1%, and 0%)
Number of subjects: 20
Study 8807168 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (RivP)
Number of subjects: 20
Study 8807168 — intervention group
Group type: COMPARATOR
Intervention: Halothane (Group H)
Number of subjects: 20
Study 1602935 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroid users
Number of subjects: 29
Study 1602935 — intervention group
Group type: COMPARATOR
Intervention: Non-users of anabolic steroids
Number of subjects: 29
Study 1602935 — intervention group
Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 29
Study 1602935 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 29
Study 6368345 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (16 mg)
Number of subjects: 30
Study 6368345 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (4 mg)
Number of subjects: 30
Study 6368345 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol (160 mg)
Number of subjects: 30
Study 31272502 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mixture (1:1) plus conventional treatment (no analgesics)
Number of subjects: 0
Study 31272502 — intervention group
Group type: COMPARATOR
Intervention: Oxygen plus conventional treatment (no analgesics)
Number of subjects: 0
Study 29652784 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicated Calcium Phosphate (SiCaP)
Number of subjects: 103
Study 29652784 — intervention group
Group type: COMPARATOR
Intervention: Bone Morphogenetic Protein (BMP)-2
Number of subjects: 103
Study 26893112 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led pain management program (12-week, 2 sessions per week)
Number of subjects: 50
Study 26893112 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 session per week for 12 weeks)
Number of subjects: 50
Study 26893112 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer volunteers (before training to week 12)
Number of subjects: 50
Study 1317296 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (1, 2, or 4 micrograms kg‐1 body weight)
Number of subjects: 18
Study 1317296 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (2 micrograms kg‐1)
Number of subjects: 18
Study 1317296 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin
Number of subjects: 18
Study 1317296 — intervention group
Group type: COMPARATOR
Intervention: ANF(99‐126)
Number of subjects: 18
Study 22863266 — intervention group
Group type: COMPARATOR
Intervention: Pegylated IFN (Peg‐IFN)‐α‐2a 180 μg qwk
Number of subjects: 391
Study 22863266 — intervention group
Group type: EXPERIMENTAL
Intervention: albIFN 900 μg q4wk
Number of subjects: 391
Study 22863266 — intervention group
Group type: EXPERIMENTAL
Intervention: albIFN 1200 μg q4wk
Number of subjects: 391
Study 22863266 — intervention group
Group type: EXPERIMENTAL
Intervention: albIFN 1500 μg q4wk
Number of subjects: 391
Study 20419738 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 29
Study 20419738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 18710995 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) alone
Number of subjects: 20
Study 18710995 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined RFA and alcohol ablation
Number of subjects: 20
Study 18710995 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol ablation alone
Number of subjects: 20
Study 18710995 — intervention group
Group type: COMPARATOR
Intervention: Baseline pain score
Number of subjects: 20
Study 16491970 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of fluoride gel weekly for 4 weeks followed by one application of fluoride gel every 3 months for one year
Number of subjects: 54
Study 16491970 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine carried out weekly for 4 weeks followed by alternative applications of fluoride gel or povidone iodine every 3 months for one year
Number of subjects: 54
Study 12215976 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric computed tomography (VCT) reconstructed paraxial images
Number of subjects: 10
Study 12215976 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric computed tomography (VCT) paraxial images with toolbar marker
Number of subjects: 10
Study 12215976 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric computed tomography (VCT) paraxial images
Number of subjects: 10
Study 12215976 — intervention group
Group type: COMPARATOR
Intervention: Conventional panoramic radiographs
Number of subjects: 10
Study 12215976 — intervention group
Group type: COMPARATOR
Intervention: Volumetric computed tomography (VCT) reconstructed panoramic images
Number of subjects: 10
Study 10894639 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week hospitalized phase II cardiac rehabilitation program
Number of subjects: 29
Study 10894639 — intervention group
Group type: COMPARATOR
Intervention: Control group (34 patients with MI who did not participate in the rehabilitation program)
Number of subjects: 29
Study 8682015 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg alteplase (n = 246)
Number of subjects: 529
Study 8682015 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg alteplase in the ambulance followed by 0.75 x 10(6) IE streptokinase in hospital (n = 90)
Number of subjects: 529
Study 8682015 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 x 10(6) IE streptokinase intravenously (n = 193)
Number of subjects: 529